leadf
logo-loader
viewMerck & Co., Inc.

Merck to invest US$1bn in Seattle Genetics as part of oncology collaboration agreement

Merck will buy 5mln shares at US$200 each plus other payments to study Seattle Genetics' candidate with its Keytruda treatment

Merck & Co., Inc. - Merck to invest US$1bn in Seattle Genetics as part of oncology collaboration agreement

Merck (NYSE:MRK) is to acquire US$1bn equity stake in Seattle Genetics, Inc. (Nasdaq:SGEN) as part of a new strategic oncology collaboration.

The companies will globally develop and commercialize Seattle Genetics’ ladiratuzumab vedotin, an investigational antibody-drug conjugate, which is currently in phase 2 clinical trials for breast cancer and other solid tumours.

The collaboration will pursue a broad joint development program evaluating ladiratuzumab vedotin as monotherapy and in combination with Merck’s anti-PD-1 therapy Keytruda in triple-negative breast cancer.

Under the terms of the agreement, Merck will buy 5mln shares at US$200 each, a 25% premium to Friday's closing price, as well as paying US$600mln upfront.

Seattle Genetics is also eligible for progress-dependent milestone payments of up to US$2.6bn.

Separately, Seattle Genetics has granted Merck an exclusive license to commercialize Tukysa, a small molecule tyrosine kinase inhibitor, for the treatment of HER2-positive cancers, in Asia, the Middle East and Latin America.

It will receive US$125mln upfront and milestones of up to US$65mln.

Seattle Genetics shot up 10% to US$164.85 while Merck remained flat at US$84.23 on Monday.

Quick facts: Merck & Co., Inc.

Price: 72.38 USD

NYSE:MRK
Market: NYSE
Market Cap: $183.12 billion
Follow

Add related topics to MyProactive

Create your account: sign up and get ahead on news and events

NO INVESTMENT ADVICE

The Company is a publisher. You understand and agree that no content published on the Site constitutes a recommendation that any particular security, portfolio of securities, transaction, or investment strategy is...

FOR OUR FULL DISCLAIMER CLICK HERE

Chimeric Therapeutics new very experienced COO has bold vision to move CAR T...

Chimeric Therapeutics (ASX: CHM) newly appointed COO Jennifer Chow joined Steve Darling from Proactive to talk about her vision for the company. Chow talks about her background working in cell therapy and how Chimeric hopes to be a big player in it. Chow also told Proactive about their lead...

58 minutes ago

2 min read